Health Condition 1: L649- Androgenic alopecia, unspecified
Conditions
Interventions
Intervention1: Low Dose Oral Minoxidil: 1.25 mg dose given O.D. orally at night before sleeping for a period of 6 months
Intervention2: Oral Finasteride: 1 mg dose given O.D. orally at night before
Sponsors
Rithvik Mudalakatte Hegde
Eligibility
Inclusion criteria
Inclusion criteria: 1. Patients with clinical features of Androgenetic Alopecia in the age group of 18 years to 50 years presenting in the Department of Dermatology Venerology and Leprosy, of A.J Institute of Medical Science, Mangalore. 2. Patients with clinical features of Androgenetic Alopecia of grades II to V according to the Norwood-Hamilton scale presenting in the Department of Dermatology Venerology and Leprosy, of A.J Institute of Medical Science, Mangalore. 3. Have Androgenetic Alopecia that in the opinion of the healthcare professional is suitable for treatment with both low dose oral minoxidil and oral finasteride.
Exclusion criteria
Exclusion criteria: 1. Patients who are using and/or continuing other treatment modalities for androgenetic alopecia. 2. Patients who have abnormal blood pressure (BP), I.e. Systolic BP 180 mmHg and Diastolic BP 120 mmHg. 3. Patients having abnormal liver function test. 4. Patients having a history of abnormal thyroid conditions. 5. Any unstable serious co-existing medical conditions. 6. Patients with a history or current evidence of any serious and/or unstable pre-existing medical or psychiatric disorder. 7. Patients diagnosed with pheochromocytoma. 8. Patients having any history of heart conditions or any abnormal cardiac examination findings. 9. Patients with a history of allergy to oral minoxidil/finasteride or its components. 10. Patients with a history of use of light or laser treatment of scalp. 11. Patients with a history of use of minoxidil (oral/topical) within 12 months. 12. Patients with a history of use of Dutasteride/ finasteride within 12 months. 13. History of receiving chemotherapy within 12 months. 14. Having a scalp skin disease at the area of treatment. 15. Patients with a history of use of systemic steroids (i.e. prednisone, methylprednisolone, etc) for at least 2 weeks within 3 months 16. Patients with a history of use of drugs that will affect hair growth such as carpronium chloride, anti-androgenic drugs (cyproterone acetate, spironolactone, ketoconazole, flutamide and bicalutamide), ketoconazole shampoo, estrogen, progesterone, prostaglandin analogs, tamoxifen, drugs induced hypertrichosis (cyclosporine diazoxide, phenytoin, psoralens) drugs induced hypotrichosis/ telogen effluvium (valproic acid, anabolic steroids, lithium and phenothiazines) 17. Patients who are unable to give informed consent. 18. Non-compliant patients.
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| increase in number & growth of hair with the use of Low Dose Oral MinoxidilTimepoint: 6 months | — |
Secondary
| Measure | Time frame |
|---|---|
| increase in number & growth of hair with the use of tablet finasterideTimepoint: 6 months | — |
Countries
India
Contacts
Public ContactRithvik Mudalakatte Hegde
A.J. Institute of Medical Sciences
Outcome results
None listed